Please use this identifier to cite or link to this item:
Title: Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
Authors: Khunti, Kamlesh
Cos, X.
Rutten, G.
First Published: 25-Oct-2013
Publisher: Elsevier for Primary Care Diabetes Europe
Citation: Primary Care Diabetes, 2014, 8 (2), pp. 119-125
Abstract: Many patients with type 2 diabetes continue to have poor glycaemic control and would benefit from insulin therapy. However, resistance to the introduction of insulin therapy can be high on both the part of the healthcare provider and the patient. A number of new, long-acting basal insulins are in development that provide good metabolic control, but with a lower risk of hypoglycaemia than currently available insulins, and greater flexibility in dosing time from day to day. These attributes may address some of the current barriers to insulin initiation and intensification that currently limit the effectiveness of diabetes care.
DOI Link: 10.1016/j.pcd.2013.09.003
ISSN: 1751-9918
eISSN: 1878-0210
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Appears in Collections:Published Articles, Dept. of Health Sciences

Files in This Item:
File Description SizeFormat 
1-s2.0-S1751991813001149-main.pdfPublished (publisher PDF)437.04 kBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.